Advertisement

European Journal of Nutrition

, Volume 52, Issue 2, pp 559–568 | Cite as

Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats

  • Sunil K. Panchal
  • Leigh Ward
  • Lindsay BrownEmail author
Original Contribution

Abstract

Background

Fruits and nuts may prevent or reverse common human health conditions such as obesity, diabetes and hypertension; together, these conditions are referred to as metabolic syndrome, an increasing problem. This study has investigated the responses to ellagic acid, present in many fruits and nuts, in a diet-induced rat model of metabolic syndrome.

Methods

Eight- to nine-week-old male Wistar rats were divided into four groups for 16-week feeding with cornstarch diet (C), cornstarch diet supplemented with ellagic acid (CE), high-carbohydrate, high-fat diet (H) and high-carbohydrate, high-fat diet supplemented with ellagic acid (HE). CE and HE rats were given 0.8 g/kg ellagic acid in food from week 8 to 16 only. At the end of 16 weeks, cardiovascular, hepatic and metabolic parameters along with protein levels of Nrf2, NF-κB and CPT1 in the heart and the liver were characterised.

Results

High-carbohydrate, high-fat diet-fed rats developed cardiovascular remodelling, impaired ventricular function, impaired glucose tolerance, non-alcoholic fatty liver disease with increased protein levels of NF-κB and decreased protein levels of Nrf2 and CPT1 in the heart and the liver. Ellagic acid attenuated these diet-induced symptoms of metabolic syndrome with normalisation of protein levels of Nrf2, NF-κB and CPT1.

Conclusions

Ellagic acid derived from nuts and fruits such as raspberries and pomegranates may provide a useful dietary supplement to decrease the characteristic changes in metabolism and in cardiac and hepatic structure and function induced by a high-carbohydrate, high-fat diet by suppressing oxidative stress and inflammation.

Keywords

Cardiovascular remodelling Ellagic acid Metabolic syndrome Non-alcoholic fatty liver disease Obesity 

Notes

Acknowledgments

This study was supported by Dr Red Nutraceuticals, Mt Nebo, QLD, Australia. This project was also partially funded by grants from The Prince Charles Hospital Foundation, Brisbane, QLD, Australia. We thank Mr. Paul Addison, School of Biomedical Sciences, and Mr. Brian Bynon, School of Veterinary Science, both at The University of Queensland, for their help with histopathological studies and plasma biochemical analyses, respectively. We also thank Dr. Thiruma V. Arumugam, School of Biomedical Sciences, The University of Queensland, for his assistance with Western blot analysis and Dr. Fiona Campbell, School of Veterinary Science, The University of Queensland, for her assistance with echocardiography.

Conflict of interest

No conflict of interest.

References

  1. 1.
    Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRefGoogle Scholar
  2. 2.
    Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA (2009) Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 8(Suppl 1):S18–S24Google Scholar
  3. 3.
    Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H et al (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722–728Google Scholar
  4. 4.
    Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J (2007) Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 44:232–263CrossRefGoogle Scholar
  5. 5.
    Powell EE, Jonsson JR, Clouston AD (2005) Steatosis: co-factor in other liver diseases. Hepatology 42:5–13CrossRefGoogle Scholar
  6. 6.
    Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44–52CrossRefGoogle Scholar
  7. 7.
    Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716CrossRefGoogle Scholar
  8. 8.
    Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689CrossRefGoogle Scholar
  9. 9.
    Adiels M, Taskinen MR, Borén J (2008) Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 8:60–64CrossRefGoogle Scholar
  10. 10.
    Lee JM, Johnson JA (2004) An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37:139–143CrossRefGoogle Scholar
  11. 11.
    Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725–734CrossRefGoogle Scholar
  12. 12.
    Sanyal AJ (2001) Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am J Gastroenterol 96:274–276CrossRefGoogle Scholar
  13. 13.
    Pessayre D, Fromenty B (2005) NASH: a mitochondrial disease. J Hepatol 42:928–940CrossRefGoogle Scholar
  14. 14.
    Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M (2010) Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 43:815–821CrossRefGoogle Scholar
  15. 15.
    Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511CrossRefGoogle Scholar
  16. 16.
    Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83:456S–460SGoogle Scholar
  17. 17.
    Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655–673CrossRefGoogle Scholar
  18. 18.
    Mari Kannan M, Darlin Quine S (2012) Mechanistic clues in the protective effect of ellagic acid against apoptosis and decreased mitochondrial respiratory enzyme activities in myocardial infarcted rats. Cardiovasc Toxicol 12:56–63CrossRefGoogle Scholar
  19. 19.
    Talcott ST, Lee JH (2002) Ellagic acid and flavonoid antioxidant content of muscadine wine and juice. J Agric Food Chem 50:3186–3192CrossRefGoogle Scholar
  20. 20.
    Ateşşahín A, Ceríbaşi AO, Yüce A, Bulmus Ö, Cikim G (2007) Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100:121–126Google Scholar
  21. 21.
    Türk G, Ateşşahín A, Sönmez M, Ceribaşi AO, Yüce A (2008) Improvement of cisplatin-induced injuries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid. Fertil Steril 89:1474–1481CrossRefGoogle Scholar
  22. 22.
    Yüce A, Ateşşahín A, Ceribaşi AO, Aksakal M (2007) Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 101:345–349CrossRefGoogle Scholar
  23. 23.
    Mari Kannan M, Darlin Quine S (2011) Pharmacodynamics of ellagic acid on cardiac troponin-T, lyosomal enzymes and membrane bound ATPases: mechanistic clues from biochemical, cytokine and in vitro studies. Chem Biol Interact 193:154–161CrossRefGoogle Scholar
  24. 24.
    Mari Kannan M, Darlin Quine S (2011) Ellagic acid ameliorates isoproterenol induced oxidative stress: evidence from electrocardiological, biochemical and histological study. Eur J Pharmacol 659:45–52CrossRefGoogle Scholar
  25. 25.
    Losso JN, Bansode RR, Trappey A 2nd, Bawadi HA, Truax R (2004) In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem 15:672–678CrossRefGoogle Scholar
  26. 26.
    Rosillo MA, Sanchez-Hidalgo M, Cardeno A, de la Lastra CA (2011) Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn’s disease. Biochem Pharmacol 82:737–745CrossRefGoogle Scholar
  27. 27.
    Gümüş M, Yüksel H, Evliyaoğlu O, Kapan M, Böyük A, Önder A, Aldemir M (2011) Effects of ellagic acid on copper, zinc, and biochemical values in serum and liver of experimental cholestatic rats. Biol Trace Elem Res 143:386–393CrossRefGoogle Scholar
  28. 28.
    Hwang JM, Cho JS, Kim TH, Lee YI (2010) Ellagic acid protects hepatocytes from damage by inhibiting mitochondrial production of reactive oxygen species. Biomed Pharmacother 64:264–270CrossRefGoogle Scholar
  29. 29.
    Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC (2009) Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam Clin Pharmacol 23:735–745CrossRefGoogle Scholar
  30. 30.
    Panchal SK, Brown L (2011) Cardioprotective and hepatoprotective effects of ellagitannins from European oak bark (Quercus petraea L.) extract in rats. Eur J Nutr. doi: 101007/s00394-011-0277-1
  31. 31.
    Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V, Kauter K, Sernia C, Campbell F et al (2011) High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 57:611–624CrossRefGoogle Scholar
  32. 32.
    Poudyal H, Campbell F, Brown L (2010) Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr 140:946–953CrossRefGoogle Scholar
  33. 33.
    Poudyal H, Panchal SK, Waanders J, Ward L, Brown L (2012) Lipid redistribution by alpha-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats. J Nutr Biochem 23:153–162CrossRefGoogle Scholar
  34. 34.
    Ward LC, Battersby KJ (2009) Assessment of body composition of rats by bioimpedance spectroscopy validation against dual-energy X-ray absorptiometry. Scand J Lab Anim Sci 36:253–261Google Scholar
  35. 35.
    Poudyal H, Panchal S, Brown L (2010) Comparison of purple carrot juice and beta-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. Br J Nutr 104:1322–1332CrossRefGoogle Scholar
  36. 36.
    Panchal SK, Poudyal H, Arumugam TV, Brown L (2011) Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J Nutr 141:1062–1069CrossRefGoogle Scholar
  37. 37.
    Diwan V, Poudyal H, Brown L (2011) Piperine attenuates cardiovascular, liver and metabolic changes in high carbohydrate, high fat-fed rats. Cell Biochem Biophys. doi: 101007/s12013-011-9306-1
  38. 38.
    Tak PP, Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107:7–11CrossRefGoogle Scholar
  39. 39.
    Bachmann K, Pardoe D, White D (1996) Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 104:400–407CrossRefGoogle Scholar
  40. 40.
    Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661CrossRefGoogle Scholar
  41. 41.
    Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130:2073S–2085SGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Department of Biological and Physical SciencesUniversity of Southern QueenslandToowoombaAustralia
  2. 2.School of Biomedical SciencesThe University of QueenslandBrisbaneAustralia
  3. 3.School of Chemistry and Molecular BiosciencesThe University of QueenslandBrisbaneAustralia

Personalised recommendations